Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia
- 16 December 2009
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 51 (1) , 61-65
Abstract
All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n = 32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p < 0.0001 and p = 0.0003, respectively). On multivariate analysis, the treatment group (DFCI vs. non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL.Keywords
This publication has 14 references indexed in Scilit:
- Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimenBritish Journal of Haematology, 2009
- Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction ChemotherapyActa Haematologica, 2008
- Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium ProtocolsJournal of Clinical Oncology, 2007
- Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993Blood, 2006
- Leukocyte count as a predictor of death during remission induction in acute myeloid leukemiaLeukemia & Lymphoma, 2006
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood, 2005
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 2004
- The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparisonBone Marrow Transplantation, 2003
- Improved Clinical Outcome for Children with T-Lineage Acute Lymphoblastic Leukemia After Contemporary Chemotherapy:A Children's Cancer Group StudyLeukemia & Lymphoma, 1996
- Adult Acute Lymphoblastic Leukaemia: The Value of Therapy IntensificationLeukemia & Lymphoma, 1991